Eastgate Biotech Corp. (ETBI) 0.0285 $ETBI
EastGate Biotech Provides Update On Its Patent Portfolio
PR Newswire - Tue Feb 03, 8:30AM CST
EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules provides update on its patent portfolio for its sub-micron self-nanoemulsifying platform technology.
EastGate Biotech Corp. Receives An NPN (Natural Product Number) For Its Product Glucora, Designed To Support Healthy Glucose Metabolism
PR Newswire - Fri Jan 23, 8:30AM CST
EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules receives an NPN (Natural Product Number) from the Natural and Non-Prescription Health Products Directorate of Health Canada for its natural product Glucora.
EastGate Biotech Corp. Names New President
PR Newswire - Tue Jan 20, 8:30AM CST
EastGate Biotech Corp., formerly EastGate Acquisitions Corporation (OTCBB: ETBI), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules has appointed Rose C. Perri as President. Ms. Perri was previously engaged in Business Development activities at EastGate Biotech. She replaces Mirjana Hasanagic who has resigned as President and who will now serve as the Vice President, Natural Products. Ms. Hasanagic will remain as a Director of EastGate's Board of Directors.
EastGate Acquisitions Announces Name Change To EastGate Biotech Corp. And New Stock Symbol
PR Newswire - Mon Dec 15, 8:30AM CST
EastGate Biotech Corp., formerly EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules, announced today that the Financial Industry Regulatory Authority ("FINRA"
approved the company's change of corporate name to EastGate Biotech Corp. from EastGate Acquisitions Corporation . The Company's new trading symbol "ETBI" is now effective.
EastGate Biotech Provides Update On Its Patent Portfolio
PR Newswire - Tue Feb 03, 8:30AM CST
EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules provides update on its patent portfolio for its sub-micron self-nanoemulsifying platform technology.
EastGate Biotech Corp. Receives An NPN (Natural Product Number) For Its Product Glucora, Designed To Support Healthy Glucose Metabolism
PR Newswire - Fri Jan 23, 8:30AM CST
EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules receives an NPN (Natural Product Number) from the Natural and Non-Prescription Health Products Directorate of Health Canada for its natural product Glucora.
EastGate Biotech Corp. Names New President
PR Newswire - Tue Jan 20, 8:30AM CST
EastGate Biotech Corp., formerly EastGate Acquisitions Corporation (OTCBB: ETBI), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules has appointed Rose C. Perri as President. Ms. Perri was previously engaged in Business Development activities at EastGate Biotech. She replaces Mirjana Hasanagic who has resigned as President and who will now serve as the Vice President, Natural Products. Ms. Hasanagic will remain as a Director of EastGate's Board of Directors.
EastGate Acquisitions Announces Name Change To EastGate Biotech Corp. And New Stock Symbol
PR Newswire - Mon Dec 15, 8:30AM CST
EastGate Biotech Corp., formerly EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules, announced today that the Financial Industry Regulatory Authority ("FINRA"
approved the company's change of corporate name to EastGate Biotech Corp. from EastGate Acquisitions Corporation . The Company's new trading symbol "ETBI" is now effective. 
